Find your next paid study

Novartis PharmaceuticalsNCT07660055

Actual pay is set by the research site.

Observational

Evaluating the Efficacy of Central Executive Training (CET) For Young Children With ADHD

Initial non-randomized trial of behavioral parent training (BPT) compared to central executive training (CET), followed by a randomized controlled trial of CET…

ADHD

Florida State UniversityNCT07784348

~$10 – $750

Actual pay is set by the research site.

NSCLC (Non-small Cell Lung Cancer)HNSCCEndometrial+5 more

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Advanced Solid Tumors

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects…

TwoStep Therapeutics, Inc.NCT07814248

Actual pay is set by the research site.

Advanced Solid TumorPDACHNSCC

First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conj…

Dementia, Early OnsetAlzheimer Dementia (AD)Mild Cognitive Impairment (MCI)+1 more

~$150 – $4,500

Actual pay is set by the research site.

Adcendo ApSNCT06597721

Genetic Studies of Early-onset Dementia

The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of…

Columbia UniversityNCT04906863

~$10 – $750

Actual pay is set by the research site.

Phase 2

Phase II Open-Label Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further ch…

Head and Neck Cancer

University of Alabama at BirminghamNCT04511078

~$75 – $2,000

Actual pay is set by the research site.

A Phase 1, Open-Label, Multicenter, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APR-1051 in Patients With Advanced Solid Tumors

The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary e…

Advanced Solid Tumor

Aprea TherapeuticsNCT06260514

Actual pay is set by the research site.

Advanced Solid TumorsMalignant Neoplasm

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and ca…

Merck Sharp & Dohme LLCNCT06818643

Actual pay is set by the research site.

Advanced Solid TumorsMetastatic Solid TumorsNon-small Cell Lung Cancer (NSCLC)+3 more

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combinati…

Revolution Medicines, Inc.NCT07397338

Actual pay is set by the research site.

Phase 2

A Pilot Study of Radiation De-Escalation for p16 Negative Oropharyngeal Cancer and p16-Negative or Positive Laryngeal and Hypopharyngeal Cancers

The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people …

Head and Neck CancerHead and Neck CarcinomaHead and Neck Neoplasms+1 more

Memorial Sloan Kettering Cancer CenterNCT05544136

~$75 – $2,000

Actual pay is set by the research site.

PARKINSON DISEASE (Disorder)Advanced Parkinson's Disease

A Randomized, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of SER-252 in Patients With Parkinson's Disease and Motor Fluctuations

This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.

Serina TherapeuticsNCT07422675

Actual pay is set by the research site.

Effect of Blood Flow Restriction (BFR) on Rehabilitation Protocols Following Anterior Cruciate Ligament Reconstruction (ACLR) With Quadricep Autograft

This project is intended to acquire objective measurements of implementing BFR rehabilitation in ACL reconstructions to show any changes upon completion of the…

AutograftsBlood Flow Restriction TherapyRehabilitation Outcome+2 more